CA2783340C - Inhibitors of akt activity - Google Patents

Inhibitors of akt activity Download PDF

Info

Publication number
CA2783340C
CA2783340C CA2783340A CA2783340A CA2783340C CA 2783340 C CA2783340 C CA 2783340C CA 2783340 A CA2783340 A CA 2783340A CA 2783340 A CA2783340 A CA 2783340A CA 2783340 C CA2783340 C CA 2783340C
Authority
CA
Canada
Prior art keywords
phenyl
pyrido
oxazin
aminocyclobutyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2783340A
Other languages
English (en)
French (fr)
Other versions
CA2783340A1 (en
Inventor
Lixin Zhang
Graham Peter Trevitt
Hugues Miel
Frank Burkamp
Timothy Harrison
Andrew John Wilkinson
Charles-Henry Fabritius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CA2783340A1 publication Critical patent/CA2783340A1/en
Application granted granted Critical
Publication of CA2783340C publication Critical patent/CA2783340C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CA2783340A 2009-12-23 2010-12-23 Inhibitors of akt activity Expired - Fee Related CA2783340C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
GB0922589.7 2009-12-23
PCT/GB2010/002329 WO2011077098A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Publications (2)

Publication Number Publication Date
CA2783340A1 CA2783340A1 (en) 2011-06-30
CA2783340C true CA2783340C (en) 2015-11-24

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2783340A Expired - Fee Related CA2783340C (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Country Status (21)

Country Link
US (1) US9221838B2 (https=)
EP (1) EP2516435B8 (https=)
JP (1) JP5923043B2 (https=)
KR (1) KR20140015157A (https=)
CN (1) CN102791708B (https=)
AU (1) AU2010334591C1 (https=)
BR (1) BR112012015677A2 (https=)
CA (1) CA2783340C (https=)
CY (1) CY1115686T1 (https=)
DK (1) DK2516435T3 (https=)
ES (1) ES2503794T3 (https=)
GB (1) GB0922589D0 (https=)
IL (1) IL220153A (https=)
MX (1) MX2012007274A (https=)
NZ (1) NZ600453A (https=)
PL (1) PL2516435T3 (https=)
PT (1) PT2516435E (https=)
RU (1) RU2579513C2 (https=)
SG (1) SG181517A1 (https=)
SI (1) SI2516435T1 (https=)
WO (1) WO2011077098A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
CN111943962A (zh) * 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
US11208478B2 (en) 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1
PE20200696A1 (es) * 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
KR102917509B1 (ko) 2017-09-07 2026-01-26 오거스타 유니버시티 리서치 인스티튜트, 인크. 특이적 akt3 활성제 및 이의 용도
GB2600384A (en) * 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2025250545A1 (en) * 2024-05-28 2025-12-04 Alterome Therapeutics, Inc. Akt1 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76853A (en) * 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) * 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8008317B2 (en) * 2005-06-10 2011-08-30 Merck Sharp & Dohme Corp. Inhibitors of akt activtiy
CA2656507C (en) * 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2299825B1 (en) 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Also Published As

Publication number Publication date
CN102791708B (zh) 2016-03-02
HK1171013A1 (en) 2013-03-15
US9221838B2 (en) 2015-12-29
CY1115686T1 (el) 2017-01-25
WO2011077098A9 (en) 2012-04-19
IL220153A0 (en) 2012-07-31
PT2516435E (pt) 2014-11-13
RU2012131115A (ru) 2014-01-27
MX2012007274A (es) 2012-10-03
EP2516435B1 (en) 2014-08-06
BR112012015677A2 (pt) 2015-06-30
CN102791708A (zh) 2012-11-21
JP2013515710A (ja) 2013-05-09
AU2010334591B2 (en) 2014-04-10
SG181517A1 (en) 2012-07-30
AU2010334591A1 (en) 2012-06-21
JP5923043B2 (ja) 2016-05-24
GB0922589D0 (en) 2010-02-10
CA2783340A1 (en) 2011-06-30
US20130116243A1 (en) 2013-05-09
IL220153A (en) 2015-05-31
WO2011077098A1 (en) 2011-06-30
PL2516435T3 (pl) 2015-01-30
NZ600453A (en) 2013-10-25
EP2516435B8 (en) 2014-10-15
AU2010334591C1 (en) 2014-07-31
ES2503794T3 (es) 2014-10-07
KR20140015157A (ko) 2014-02-06
SI2516435T1 (sl) 2014-12-31
RU2579513C2 (ru) 2016-04-10
DK2516435T3 (da) 2014-10-13
EP2516435A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CA2783340C (en) Inhibitors of akt activity
AU2019201352B2 (en) Bromodomain inhibitors
US8546376B2 (en) Pharmaceutical compounds
AU2014241152B2 (en) Benzimidazolone derivatives as bromodomain inhibitors
ES2791401T3 (es) Compuestos tricíclicos y sus usos en medicina
KR102732404B1 (ko) 파르네소이드 x 수용체 조정제로서의 알켄 화합물
US20120309739A1 (en) Akt / pkb inhibitors
EP3704114B1 (en) Spirocyclic compounds as farnesoid x receptor modulators
CN112409385B (zh) 氮杂芳基化合物及其应用
EP4055013A1 (en) Wdr5 inhibitors and modulators
KR20200083529A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
AU2013237184A1 (en) 6- (4- (1 -amino- 3 -hydroxycyclobutyl) phenyl) - 5 - phenyl (furo, thieno or pyrrolo) [2, 3-D] pyrimidin- 4 - one derivatives for the treatment of cancer
JP5937201B2 (ja) 2−アミノ−3−(イミダゾール−2−イル)ピリジン−4−オン誘導体及びvegf受容体キナーゼ阻害剤としてのその使用
HK1171013B (en) Inhibitors of akt activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181224